Anti-Helicobacter pylori therapy in India: Differences in eradication efficiency associated with particular alleles of vacuolating cytotoxin (vacA) gene

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 2, 2003, Pages 190-195

  Chaudhuri, Sujit ^a   Chowdhury, Abhijit ^a,d   Datta, Simanti ^b   Mukhopadhyay, Asish K ^c   Chattopadhya, Santanu ^b   Saha, Dhira R ^b   Dhali, Gopal ^a   Santra, Amal ^a   Balakrish Nair, G ^b   Bhattacharya, Sujit ^b   Berg, Douglas E ^c  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (India)

Author keywords

Clarithromycin based triple therapy; Helicobacter pylori eradication; vacA genotypes

Indexed keywords

AMOXICILLIN; BACTERIAL PROTEIN; CLARITHROMYCIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG; VACUOLATING CYTOTOXIN PROTEIN;

ADULT; ALLELE; ARTICLE; BACTERIAL GENE; BACTERIUM CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DUODENUM CANCER; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL ENDOSCOPY; GENETIC ANALYSIS; GENOTYPE; HEALTH CARE COST; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; PERSISTENT INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; ULCER HEALING;

EID: 0037300006     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.02944.x     Document Type: Article

References (31)

1. Cover TL, Berg DE, Blaser MJ, Mobley HLT. H. pylori pathogenesis. In: Groisman EA, ed. Principles of Bacterial Pathogenesis. New York: Academic Press, 2001; 509-58.
2. Kuipers EJ, Blaser MJ. Helicobacter pylori and gastro duodenal disorders. In: Scheld WM, Armstrong D, Hughes JM, eds. Emerging Infections I. Washington DC: ASM Press, 1998; 191-206.
3. Rauws EA, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990; 335: 1233-5.
4. Forbes GM, Glaser ME, Cullen DJ et al. Duodenal ulcer treated with H. pylori eradication: seven years follow-up. Lancet 1994; 343: 258-60.
5. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-52.
6. Laheij RJF, van Rossum LGM, Jansen JBMJ et al. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta analysis. Aliment. Pharmacol. Ther. 1999; 13: 857-64.
7. Gupta VK, Dhar A, Srinivasan S et al. Eradication of H. pylori in a developing country: comparison of Lansoprazole versus omeprazole with norfloxacin in a dual therapy study. Am. J. Gastroenterol. 1997; 92: 1140-2.
8. Ahuja V, Dhar A, Bal C et al. Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. Aliment. Pharmacol. Ther. 1998; 12: 551-5.
9. Bhasin DK, Sharma BC, Sinha SR et al. Helicobacter pylori eradication: comparison of three treatment regimens in India. J. Clin. Gastroenterol. 1999; 28: 348-51.
10. Akopyanz N, Bukanov NO, Westblom TU et al. DNA diversity among clinical isolates of Helicobacter pylori detected by PCR based RAPD fingerprinting. Nucleic Acids Res. 1992; 20: 5137-42.
11. Logan RP, Berg DE. Genetic diversity of Helicobacter pylori. Lancet 1996; 348: 1462-3.
12. Achtman M, Azuma T, Berg DE et al. Recombination and clonal groupings within Helicobacter pylori from different geographical regions. Molec. Microbiol. 1999; 32: 459-70.
13. Kersulyte D, Mukhopadhyay AK, Velapatino B et al. Differences in genotypes of Helicobacter pylori from different human populations. J. Bacteriol. 2000; 182: 3210-18.
14. Mukhopadhyay AK, Kersulyte D, Jeong JY et al. Distinctiveness of genotype of Helicobacter pylori in Calcutta. J. Bacteriol. 2000; 182: 3219-27.
15. Chowdhury A, Berg DE, Jeing JY et al. Metronidazole resistance in Helicobacter pylori: magnitude, mechanism and implication for India. Indian J. Gastroenterol. 2002; 21: 23-8.
16. Ausubel FM, Brent R, Kingston RE et al. Current Protocols in Molecular Biology. New York: Greene Publishing and Wiley-Interscience, I993.
17. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998; 115: 1278-82.
18. Graham DY. Antibiotic resistance in Helicobacter pylori: Implications for therapy. Gastroenterology 1998; 115: 1272-7.
19. Thomson CP, Putimood A, Mathan M et al. Comparison of two triple drug regimens in eradication and healing of H. pylori positive duodenal ulcers (Abstract). Indian J. Gastroenterol. 1996; 15 (Suppl. 1): A85.
20. Wang WH, Wong BC, Lam SK. Helicobacter pylori infection: Pooled analysis of Helicobacter pylori eradication regimes in Asia, J. Gastroenterol. Hepatol. 2000; 15: 1007-17.
21. Megraud F, Marshall BJ. How to treat Helicobacter pylori. First line, second line and future therapies. Gastroenterol. Clin. North Am. 2000; 29: 759-73.
22. Goodwin A, Kersulyte D, Sisson G et al. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen insensitive NADPH nitroreductase. Mol. Microbiol. 1998; 28: 383-93.
23. Jeong JY, Mukhopadhyay AK, Dailidiene D et al. Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes cause moderate and high level metronidazole resistance in Helicobacter pylori. J. Bacteriol. 2000; 182: 5082-90.
24. Debets OK, Sparius YJM, Khsters JG et al. Grants. Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol. Lett. 1996; 142: 37-42.
25. Fallone CA, Loo V, Joseph L et al. Predictors of failure of Helicobacter pylori eradication and predictors of ulcer recurrence: a randomized controlled trial. Clin. Invest. Med. 1999; 22: 185-94.
26. Dore MP, Leandro G, Realdi G et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta analytical approach. Dig. Dis. Sci. 2000; 45: 68-76.
27. Perri F, Festa V, Quitadamo M et al. cag positive status is a risk factor for unsuccessful H. pylori eradication (Abstract). Gut 1999; 45 (Suppl. III): A33.
28. van Doorn LJ, Schneenberger PM, Nouhan N et al. Importance of Helicobacter pylori cagA and vacA status for efficacy of antibiotic treatment. Gut 2000; 46: 321-6.
29. Rudi J, Reuter S, Kuck D et al. Relevance of bacterial vacA genotypes and cagA status in the efficacy of Helicobacter pylori eradication (Abstract). Gut 1999; 45 (Suppl. III): A30.
30. Go MF, Li L, Frantz G, Laine L. Hp cagA and vacA from US duodenal ulcer (DU) patients and association with eradication. Gut 1999; 45 (Suppl. III): A108.
31. Pagliaccia C, De Bernard M, Lupetti P et al. The m2 form of the Helicobacter pylori cytotoxin has cell type specific vacuolating activity. Proc. Natl Acad. Sci. USA 1998; 95: 10212-17.